View in EDS

94P Patient-reported outcomes (PROs) following sintilimab (sint) plus pemetrexed (pem) and platinum (plt) based chemotherapy as first-line therapy for locally advanced or metastatic nonsquamous NSCLC: A randomized, double-blind, phase III study (Orient-11)

Saved in:
Bibliographic Details
Title: 94P Patient-reported outcomes (PROs) following sintilimab (sint) plus pemetrexed (pem) and platinum (plt) based chemotherapy as first-line therapy for locally advanced or metastatic nonsquamous NSCLC: A randomized, double-blind, phase III study (Orient-11)
Authors: Fang, J.1 (AUTHOR), Zhao, Y.2,3 (AUTHOR), Han, B.4 (AUTHOR), Chen, G.5 (AUTHOR), Yang, Z.6 (AUTHOR), Bi, M.7 (AUTHOR), Zhang, L.2,8 (AUTHOR), Molife, C.9 (AUTHOR)
Source: Annals of Oncology. 2021 Supplement 7, Vol. 32, pS1415-S1415. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2021.10.112